Drugs like Ozempic, Wegovy, and Mounjaro are helping millions of people lose weight and manage type 2 diabetes
10 For conditions like multiple sclerosis and amyotrophic lateral sclerosis, the treatments we have either calm the immune system or manage symptoms, but they cannot reverse the damage that is already been done
Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Missing doses can significantly impact your treatment effectiveness, potentially delaying your weight loss results or blood sugar management
Wegovy highlights of prescribing information, Novo Nordisk (2024) The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy, Scientific Reports (2024) Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study, Frontiers in Pharmacology (2022) Most GLP-1 medications correlated with a lower likelihood of anxiety and depression diagnoses, Epic Research (2024) Dopamine release in the midbrain promotes anxiety, Biological Psychology (2021) Dopamine primes the brain for enhanced vigilance, MIT News (2018) Why your cardiologist may prescribe semaglutide (Wegovy), Yale Medicine (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
